Literature DB >> 12084877

Differential expression of chemokines in inflammatory myopathies.

Jan L De Bleecker1, Boel De Paepe, Iris E Vanwalleghem, J Michael Schröder.   

Abstract

BACKGROUND: Chemokines represent a family of small-molecular-weight cytokines that recruit and activate inflammatory cells in response to inflammation. Invasion of cytotoxic memory T cells and macrophages in nonnecrotic muscle fibers characterizes polymyositis and sporadic inclusion body myositis. Dermatomyositis is a complement-mediated endotheliopathy. Elucidation of the mechanisms guiding lymphocyte diapedesis and trafficking could lead to selective therapeutic interventions.
METHODS: Immunoblots and multistep immunofluorescence studies with non-cross-reactive antibodies recognizing interleukin-8, monocyte chemoattractant protein-1 (MCP-1), MCP-3, TARC (thymus and activation regulated cytokine), and RANTES (regulated upon activation, normal T-cell expressed and secreted), using appropriate positive and negative controls. In situ hybridization was used to localize MCP-1 mRNA.
RESULTS: MCP-1 protein was strongly expressed on T cells and a subset of macrophages actively invading a proportion of the nonnecrotic muscle fibers in polymyositis and inclusion body myositis alike. Capillaries and arterioles in the vicinity of endomysial inflammatory foci were immunoreactive for MCP-1, with faint or no expression in unaffected parts of the tissue. By contrast, widespread and strong endothelial MCP-1 expression occurred on perifascicular and perimysial endothelia in dermatomyositis, also at sites remote from inflammatory infiltrates. In some control specimens, a subset of capillaries also expressed MCP-1, possibly reflecting a role of this chemokine in normal immune surveillance. MCP-1 mRNA was detected in scattered macrophages in each inflammatory myopathy. All other chemokines were absent.
CONCLUSION: Chemokines are differentially expressed in the symptomatic stage of inflammatory myopathies. MCP-1 plays a major role in the myocytotoxicity in polymyositis and inclusion body myositis. MCP-1 may be induced by membranolytic attack complex binding to endothelial cells in dermatomyositis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084877     DOI: 10.1212/wnl.58.12.1779

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

Review 1.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

Review 2.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 3.  Dermatomyositis.

Authors:  M S Krathen; D Fiorentino; V P Werth
Journal:  Curr Dir Autoimmun       Date:  2008

4.  The inflammatory milieu in idiopathic inflammatory myositis.

Authors:  Ann M Reed; Floranne Ernste
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 5.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

6.  Immunotherapy of inflammatory myopathies: practical approach and future prospects.

Authors:  Marinos C Dalakas
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

7.  A randomized, pilot trial of etanercept in dermatomyositis.

Authors: 
Journal:  Ann Neurol       Date:  2011-06-17       Impact factor: 10.422

8.  Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin.

Authors:  John H Boyd; Maziar Divangahi; Linda Yahiaoui; Dusanka Gvozdic; Salman Qureshi; Basil J Petrof
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

9.  Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.

Authors:  Ann M Reed; Erik Peterson; Hatice Bilgic; Steven R Ytterberg; Shreyasee Amin; Molly S Hein; Cynthia S Crowson; Floranne Ernste; Emily Baechler Gillespie
Journal:  Arthritis Rheum       Date:  2012-12

10.  Interaction of PRP4 with Kruppel-like factor 13 regulates CCL5 transcription.

Authors:  Boli Huang; Yong-Tae Ahn; Lisa McPherson; Carol Clayberger; Alan M Krensky
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.